WARNING: SEVERE MYELOSUPPRESSION AVOPEF can cause severe myelosuppression resulting in infection or bleeding [see Warnings and Precautions (5.1)]. Do not administer AVOPEF to patients with absolute neutrophil counts of less than 500 cells/mm 3 or platelets less than 50,000 cells/mm 3 [see Warnings and Precautions (5.1)].
Monitor complete blood cell counts, prior to the administration of AVOPEF and before each subsequent cycle, and at appropriate intervals during and after therapy [see Warnings and Precautions (5.1)]. WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning. AVOPEF can cause severe myelosuppression resulting in infection or bleeding.
(5.1) Do not administer AVOPEF to patients with absolute neutrophil counts of less than 500 cells/mm 3 or platelets less than 50,000 cells/mm 3. (5.1) Monitor complete blood cell counts, prior to the administration of AVOPEF and before each subsequent cycle, and at appropriate intervals during and after therapy. (5.1)
Use: Labeled indications
- AVOPEF is a topoisomerase inhibitor indicated, in combination with other chemotherapy and/or immunotherapy, for the treatment of adult patients with: Refractory testicular cancer
- Small cell lung cancer
Full indications and usage US FDA label
1 INDICATIONS AND USAGE AVOPEF is a topoisomerase inhibitor indicated, in combination with other chemotherapy and/or immunotherapy, for the treatment of adult patients with: Refractory testicular cancer (1.1) Small cell lung cancer (1.2) 1.1 Refractory Testicular Cancer AVOPEF, in combination with chemotherapy, is indicated for the treatment of refractory testicular cancer in adult patients. 1.2 Small Cell Lung Cancer AVOPEF, in combination with chemotherapy and immunotherapy, is indicated for the first-line treatment of small cell lung cancer (SCLC) in adult patients.
Contraindications
4 CONTRAINDICATIONS AVOPEF is contraindicated in patients with hypersensitivity to etoposide or any of its excipients. Hypersensitivity to etoposide or any of its excipients. (4)
US FDA labelDosing: Adult
- Refractory Testicular Cancer: 50 mg/m 2 to 100 mg/m 2 administered intravenously daily on Days 1 to 5, or 100 mg/m 2 administered intravenously daily on Days 1, 3 and 5. (2.2)
- Small Cell Lung Cancer: 35 mg/m 2 administered intravenously daily on days 1 to 4, or 50 mg/m 2 administered intravenously daily on days 1 to 5. (2.3)
- Dilute AVOPEF prior to intravenous infusion over 30- to 60-minutes. (2.5)
2.1 Important Dosage and Administration Information
2.1 Important Dosage and Administration Information Dilute AVOPEF to a final concentration of 0.2 to 0.4 mg/mL prior to administration [see Dosage and Administration (2.5)]. Administer diluted AVOPEF by intravenous infusion over 30 to 60 minutes to reduce the risk of infusion-related reactions including hypotension [see Dosage and Administration (2.5)].
Before each AVOPEF administration and at appropriate intervals during and after therapy, monitor complete blood counts with differential and serum albumin [see Warnings and Precautions (5.1, 5.5)]. If severe reactions occur, reduce the dosage or discontinue AVOPEF and take appropriate corrective measures according to the clinical judgment of the healthcare provider.
2.2 Recommended Dosage for Refractory Testicular Cancer
2.2 Recommended Dosage for Refractory Testicular Cancer The recommended dosage of AVOPEF is: 50 mg/m 2 to 100 mg/m 2 administered intravenously daily on Days 1 to 5, or 100 mg/m 2 administered intravenously daily on Days 1, 3 and 5 Repeat treatment cycles every 3 to 4 weeks.
2.3 Recommended Dosage for Small Cell Lung Cancer
2.3 Recommended Dosage for Small Cell Lung Cancer The recommended dosage of AVOPEF is: 35 mg/m 2 administered intravenously daily on Days 1 to 4, or 50 mg/m 2 administered intravenously daily on Days 1 to 5 Repeat treatment cycles every 3 to 4 weeks.
2.4 Recommended Dosage in Patients with Renal Impairment
2.4 Recommended Dosage in Patients with Renal Impairment No dosage modification is recommended for patients with creatinine clearance (CLcr) > 50 mL/min. The recommended dosage of AVOPEF in patients with CLcr of 15 to 50 mL/min is listed in Table 1. Table 1: Recommended Dosage of AVOPEF in Patients with Creatinine Clearance of 15 to 50 mL/min *Repeat treatment cycles every 3 to 4 weeks.
Recommended AVOPEF Dosage * Refractory Testicular Cancer 37 mg/m 2 to 75 mg/m 2 Days 1 through 5 75 mg/m 2 Days 1, 3 and 5 Small Cell Lung Cancer 26 mg/m 2 Days 1 through 4 37 mg/m 2 Days 1 through 5 A recommended dosage of AVOPEF has not been established for patients with creatinine clearance < 15 mL/min.
2.5 Preparation for Intravenous Administration
2.5 Preparation for Intravenous Administration Preparation AVOPEF is a hazardous drug. Follow applicable special handling and disposal procedures. [see References (15)]. Dilute AVOPEF with either 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, to a final concentration of 0.2 to 0.4 mg/mL. If solutions of AVOPEF are prepared at concentrations above 0.4 mg/mL, precipitation may occur.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Administration Do not administer AVOPEF by rapid intravenous injection. To reduce the risk of infusion-related reactions including hypotension, administer diluted AVOPEF intravenously over 30 to 60 minutes.
A longer duration of administration may be used if there is a large volume of fluid to be infused. Storage AVOPEF, diluted to a concentration of 0.2 mg/mL is stable for 96 hours or diluted to a concentration of 0.4 mg/mL is stable for 24 hours at room temperature (25°C) under normal room fluorescent light in polyvinyl chloride (PVC) container.
After first use, store the partially used multiple-dose vial in the original carton at controlled room temperature, 20°C to 25°C (68°F to 77°F) for up to 28 days. Discard unused portion of the multiple-dose vial after 28 days.
Dosing: Altered kidney function
2.4 Recommended Dosage in Patients with Renal Impairment No dosage modification is recommended for patients with creatinine clearance (CLcr) > 50 mL/min. The recommended dosage of AVOPEF in patients with CLcr of 15 to 50 mL/min is listed in Table 1. Table 1: Recommended Dosage of AVOPEF in Patients with Creatinine Clearance of 15 to 50 mL/min *Repeat treatment cycles every 3 to 4 weeks.
Recommended AVOPEF Dosage * Refractory Testicular Cancer 37 mg/m 2 to 75 mg/m 2 Days 1 through 5 75 mg/m 2 Days 1, 3 and 5 Small Cell Lung Cancer 26 mg/m 2 Days 1 through 4 37 mg/m 2 Days 1 through 5 A recommended dosage of AVOPEF has not been established for patients with creatinine clearance < 15 mL/min.
8.6 Renal Impairment Reduce the dose of AVOPEF in patients with creatinine clearance (CLcr) of 15 to 50 mL/min [see Dosage and Administration (2.4)]. No dosage modification is recommended for patients with CLcr > 50 mL/min.
Patients with Renal Impairment Patients with impaired renal function have exhibited reduced total body clearance, increased AUC, and a lower volume of distribution at steady state.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of AVOPEF have not been established in pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of etoposide for the treatment of refractory testicular tumors did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. Other reported clinical experience demonstrated that patients 65 years and older experienced more myelosuppression, anorexia, mucositis, dehydration, somnolence, elevated blood urea nitrogen (BUN), infectious complications and alopecia compared to younger patients.
In general, dosage selection for an older patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Administration
2.1 Important Dosage and Administration Information Dilute AVOPEF to a final concentration of 0.2 to 0.4 mg/mL prior to administration [see Dosage and Administration (2.5) ]. Administer diluted AVOPEF by intravenous infusion over 30 to 60 minutes to reduce the risk of infusion-related reactions including hypotension [see Dosage and Administration (2.5) ]. Before each AVOPEF administration and at appropriate intervals during and after therapy, monitor complete blood counts with differential and serum albumin [see Warnings and Precautions (5.1, 5.5) ]. If severe reactions occur, reduce the dosage or discontinue AVOPEF and take appropriate corrective measures according to the clinical judgment of the healthcare provider.
2.5 Preparation for Intravenous Administration Preparation AVOPEF is a hazardous drug. Follow applicable special handling and disposal procedures. [see References (15) ]. Dilute AVOPEF with either 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, to a final concentration of 0.2 to 0.4 mg/mL. If solutions of AVOPEF are prepared at concentrations above 0.4 mg/mL, precipitation may occur. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Administration Do not administer AVOPEF by rapid intravenous injection. To reduce the risk of infusion-related reactions including hypotension, administer diluted AVOPEF intravenously over 30 to 60 minutes. A longer duration of administration may be used if there is a large volume of fluid to be infused. Storage AVOPEF, diluted to a concentration of 0.2 mg/mL is stable for 96 hours or diluted to a concentration of 0.4 mg/mL is stable for 24 hours at room temperature (25°C) under normal room fluorescent light in polyvinyl chloride (PVC) container. After first use, store the partially used multiple-dose vial in the original carton at controlled room temperature, 20°C to 25°C (68°F to 77°F) for up to 28 days. Discard unused portion of the multiple-dose vial after 28 days.
US FDA labelDosage forms
Philippines
- ) solution for injection: 20 mg/mL (100 mg/5 mL, 100 mg/5 mL (20 mg/mL
- Solution for injection: 100 mg/5 mL
- ) solution for i.v injection: 20 mg/mL (100 mg/5 mL, 20 mg/mL (50 mg/2.5 mL, 100 mg/5 mL and 200 mg/10 mL
- Concentrate for i.v. infusion or oral solution: 20 mg/mL
Registered products in the Philippines
11 products registered with the Food and Drug Administration (FDA) Philippines list Etoposide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products11
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
EbeposidEtoposide | 20 mg/mL Concentrate for I.V. Infusion or Oral SolutionAmber Glass Vial x 2.5 mL, 5 mL & 10 mL (Box of 1's) | RxVAT-exempt | Fareva Unterach GmbHAustria | Sandoz Philippines Corporation | DR-XY28457 | Mar 26, 2028 | |
Etolon 100Etoposide | 20mg/mL (100mg/5mL) Solution for InjectionUSP Type I Clear and Colorless Glass Vial with Red Flip-off Seal x 5 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E. Medica, Inc. | DRP-8724 | Feb 21, 2031 | |
EtopaEtoposide | 100 mg/5 mL Solution for Injection (I.V.)5 mL USP Type I Flint Glass Vial (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | AGB Pharmaceutical Trading & Consultancy Corp. | DRP-4915 | Nov 13, 2028 | |
EtopisiEtoposide | 20 mg/mL (100 mg/5 mL) Solution For Injection (I.V.)USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Flip-off Seal x 5 mL (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International Corporation | DRP--19158 | Nov 11, 2031 | |
EtopojectEtoposide | 100 mg/5 mL (20 mg/mL) Solution for Injection (I.V.)5 mL USP Type I Flint Glass Vial (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Genace Pharma DistributorImporter: AGB Pharmaceutical Trading & Consultancy Corp. | DRP-4915-01 | Nov 13, 2028 | |
EtopulEtoposide | 100 mg/5 mL Solution for Injection (I.V.)Amber glass ampoule x 5mL (Box of 10's) | RxVAT-exempt | Korea United Pharm, Inc.Korea | Qualimed Pharma Inc. | DR-XY25051 | Apr 29, 2029 | |
EtosaphsideEtoposide | 20 mg/mL (50 mg/2.5 mL, 100 mg/5 mL and 200 mg/10 mL) Solution For I.V InjectionUSP Type I Clear Glass Vial (2.5 mL, 5 mL & 10 mL net content) [Box of 1's] | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13185 | Dec 22, 2027 | |
MPL EtopaxilEtoposide | 100 mg/5 mL Solution for Injection (I.V.)5 mL USP Type I Flint Glass Vial (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Multi Product Line Pharma, Inc.Importer: AGB Pharmaceutical Trading & Consultancy Corp. | DRP-4915-02 | Nov 13, 2028 | |
NzytopEtoposide | 100 mg/5mL Solution for Injection (IV)USP Type I flint vial x 5 mL (Box of 1's) | RxVAT-exempt | Naprod Lifesciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc. | DRP-2876 | Nov 30, 2027 | |
ResedaEtoposide | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Clear and Colorless Glass Vial with Red Flip-off Seal x 5 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Kaufmann Pharma Inc.Importer: I.E. Medica, Inc. | DRP-8724-01 | Feb 21, 2031 | |
SaphtosideEtoposide | 20mg/mL (100mg/5mL) Solution For I.V Injection5 mL USP Type I Clear Glass Ampoule (Box of 10's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13184 | Jan 5, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 100 mg/5 mL (20 mg/mL) and 500 mg/25 mL (20 mg/mL) of etoposide as a sterile, clear, colorless to light yellow liquid in a multiple-dose vial. Injection: 100 mg/5 mL (20 mg/mL) and 500 mg/25 mL (20 mg/mL) in a multiple-dose vial. (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Severe Myelosuppression: Monitor complete blood counts before each AVOPEF administration and at appropriate intervals during and after therapy. Interrupt AVOPEF for absolute neutrophil counts below 500 cells/mm 3 or platelet counts below 50,000 cells/mm 3. (5.1)
- Hypersensitivity and Infusion-Related Reactions: At the first sign of hypersensitivity, stop the infusion and administer volume expanders, corticosteroids, antihistamines, and pressor agents as appropriate. Permanently discontinue AVOPEF in patients who experience a severe hypersensitivity reaction. Hypotension has occurred after rapid intravenous injection. (5.2)
- Extravasation Resulting in Tissue Necrosis: Extravasation of etoposide can result in swelling, pain, cellulitis, and tissue necrosis. (5.3)
- Secondary Leukemia: Secondary leukemia has occurred with use of etoposide. (5.4)
- Risk of Increased AVOPEF Toxicity with Low Serum Albumin: Monitor serum albumin during treatment with AVOPEF. Patients with low serum albumin may have increased concentrations of unbound etoposide and may be at an increased risk for etoposide associated adverse reactions. (5.5)
- Alcohol Content: The alcohol content in a dose of AVOPEF may affect the central nervous system. This may include impairment of a patient's ability to drive or use machines immediately after infusion. (5.6)
- Embryo-Fetal Toxicity: AVOPEF can cause …
5.1 Severe Myelosuppression
5.1 Severe Myelosuppression AVOPEF can cause severe and fatal myelosuppression, including neutropenia, febrile neutropenia, anemia, and thrombocytopenia. Monitor complete blood counts with differential before each AVOPEF administration and at appropriate intervals during and after treatment with AVOPEF. Do not administer AVOPEF to patients with absolute neutrophil counts of less than 500 cells/mm 3 or platelets less than 50,000 cells/mm 3.
5.2 Hypersensitivity and Infusion-Related Reactions
5.2 Hypersensitivity and Infusion-Related Reactions AVOPEF can cause severe and fatal infusion-related reactions including anaphylactic reactions characterized by chills, fever, tachycardia, bronchospasm, dyspnea and hypotension [see Adverse Reactions (6.1)]. Hypertension and flushing have occurred. At the first sign of hypersensitivity, stop the infusion and administer volume expanders, corticosteroids, antihistamines, and pressor agents as appropriate.
Permanently discontinue AVOPEF in patients who experience a severe hypersensitivity reaction. Hypotension due to rapid intravenous injection has also occurred. To reduce the risk of hypotension due to an infusion-related reaction, administer AVOPEF by intravenous infusion over 30 to 60 minutes [see Dosage and Administration (2.5)].
5.3 Extravasation Resulting in Tissue Necrosis
5.3 Extravasation Resulting in Tissue Necrosis Extravasation of etoposide can result in swelling, pain, cellulitis, and tissue necrosis.
5.4 Secondary Leukemia
5.4 Secondary Leukemia Secondary leukemia has occurred with use of etoposide.
5.5 Risk of Increased
5.5 Risk of Increased AVOPEF Toxicity with Low Serum Albumin Etoposide is highly protein-bound. Patients with low serum albumin may have increased concentrations of unbound etoposide and may be at an increased risk for etoposide associated adverse reactions. Monitor for increased adverse reactions during treatment with AVOPEF in patients with low serum albumin.
5.6 Alcohol Content
5.6 Alcohol Content The alcohol content in a dose of AVOPEF may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized. Consideration should be given to the alcohol content in AVOPEF on the ability to drive or use machines immediately after the infusion.
Each administration of AVOPEF at 100 mg/m 2 delivers 1.5 g/m 2 of ethanol. For a patient with a BSA of 2.0 m² this would deliver 3.0 grams of ethanol [see Description (11)]. Other etoposide products may have a different amount of alcohol or no alcohol.
5.7 Embryo-Fetal Toxicity
5.7 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, AVOPEF can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, intravenous or intraperitoneal administration of etoposide to pregnant animals during the period of organogenesis caused embryo-fetal mortality and structural abnormalities at doses below the recommended human dose of 50 mg/m 2 based on body surface area (BSA).
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise female patients of reproductive potential to use effective contraception during treatment with AVOPEF and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with AVOPEF and for 4 months after the last dose [see Use in Specific Populations (8.1, 8.3)].
Drug interactions
- CYP3A Inhibitors and CYP3A Inducers: Avoid concomitant use of strong CYP3A inhibitors and strong CYP3A inducers with AVOPEF. (7.1)
- Vitamin K Antagonists: Monitor INR more frequently and modify the dosage of the vitamin K antagonists as appropriate. Co-administration of AVOPEF with warfarin can result in elevated international normalized ratio (INR). (7.2)
7.1 Effect of Other Drugs
7.1 Effect of Other Drugs on AVOPEF CYP3A Inhibitors Avoid concomitant use of strong CYP3A inhibitors. Etoposide is a CYP3A4 substrate. Strong CYP3A inhibitors may increase etoposide exposure, which may increase the risk of AVOPEF-associated adverse reactions [see Clinical Pharmacology (12.3)]. CYP3A Inducers Avoid concomitant use of strong CYP3A inducers.
Etoposide is a CYP3A4 substrate. Strong CYP3A inducers may reduce etoposide exposure, which may decrease the effectiveness of AVOPEF [see Clinical Pharmacology (12.3)].
7.2 Effect
7.2 Effect of AVOPEF on Other Drugs Vitamin K Antagonists Monitor INR more frequently and modify the dosage of the vitamin K antagonists as appropriate. Co-administration of AVOPEF with warfarin can result in elevated international normalized ratio (INR).
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
O-demethylation occurs through CYP3A to the active catechol metabolite.
7 DRUG INTERACTIONS CYP3A Inhibitors and CYP3A Inducers : Avoid concomitant use of strong CYP3A inhibitors and strong CYP3A inducers with AVOPEF.
( 7.2 ) 7.1 Effect of Other Drugs on AVOPEF CYP3A Inhibitors Avoid concomitant use of strong CYP3A inhibitors.
Etoposide is a CYP3A4 substrate.
Strong CYP3A inhibitors may increase etoposide exposure, which may increase the risk of AVOPEF-associated adverse reactions [see Clinical Pharmacology (12.3) ].
CYP3A Inducers Avoid concomitant use of strong CYP3A inducers.
Strong CYP3A inducers may reduce etoposide exposure, which may decrease the effectiveness of AVOPEF [see Clinical Pharmacology (12.3) ]. 7.2 Effect of AVOPEF on Other Drugs Vitamin K Antagonists Monitor INR more frequently and modify the dosage of the vitamin K antagonists as appropriate.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling. Severe Myelosuppression [see Warnings and Precautions (5.1)] Hypersensitivity and Infusion-Related Reactions [see Warnings and Precautions (5.2)] Extravasation Resulting in Tissue Necrosis [see Warnings and Precautions (5.3)] Secondary Leukemia [see Warnings and Precautions (5.4)] Risk of Increased AVOPEF Toxicity with Low Serum Albumin [see Warnings and Precautions (5.5)] Alcohol Content [see Warnings and Precautions (5.6)] The most common adverse reactions are myelosuppression, hypersensitivity, nausea/vomiting, and alopecia.
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact AVYXA Pharma, LLC at 1-888-520-0954 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Blood and lymphatic system disorders: acute leukemia, myelosuppression Eye disorders: transient cortical blindness Gastrointestinal disorders: abdominal pain, anorexia, constipation, diarrhea, dysgeusia, dysphagia, esophagitis, mucositis, nausea, stomatitis and vomiting General disorders and administration site conditions: fatigue, fever, and infusion site extravasation with necrosis Hepatobiliary disorders: hepatotoxicity, metabolic acidosis Immune system disorders: allergic reaction, anaphylactic reaction (including chills, fever, tachycardia, bronchospasm, dyspnea, hypotension, hypertension, flushing, facial swelling, tongue swelling, coughing, diaphoresis, cyanosis, tightness in throat, laryngospasm, back pain, loss of consciousness, hypersensitivity-associated apnea), hypersensitivity, infusion-related reaction.
Infections: febrile neutropenia Nervous system disorders: optic neuritis, peripheral neuropathy and seizure Respiratory, thoracic and mediastinal disorders: interstitial pneumonitis and pulmonary fibrosis Skin and subcutaneous tissue disorders: alopecia, pigmentation changes (including pigmented bands in nails, skin darkening and discoloration of tongue and teeth), pruritic erythematous maculopapular rash, pruritus, radiation recall dermatitis, rash, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and urticaria Vascular disorders: hypotension following rapid intravenous administration [see Dosage and Administration (2.5)], perivasculitis
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings in animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], AVOPEF can cause fetal harm when administered to a pregnant woman. There are no available data on the use of AVOPEF in pregnant women to inform a drug-associated risk. AVOPEF contains alcohol which can interfere with neurobehavioral development [see Clinical Considerations].
In animal reproduction studies, intravenous or intraperitoneal administration of etoposide to pregnant animals during the period of organogenesis caused embryo-fetal mortality and structural abnormalities at doses below the recommended human dose of 50 mg/m 2 based on body surface area (BSA). Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
Advise female patients of reproductive potential to use effective contraception during treatment with AVOPEF and for 6 months after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and of miscarriage is 15% to 20%, respectively.
Clinical Considerations AVOPEF contains alcohol [see Warnings and Precautions (5.6)]. Published studies have demonstrated that alcohol is associated with fetal harm including central nervous system abnormalities, behavioral disorders, and impaired intellectual development. Data Animal Data In rats, an intravenous etoposide dose of 0.4 mg/kg/day (approximately 0.05 times the human dose of 50 mg/m 2 based on BSA) during organogenesis caused maternal toxicity, embryotoxicity, and teratogenicity (skeletal abnormalities, exencephaly, encephalocele, and anophthalmia); higher doses of 1.2 and 3.6 mg/kg/day (approximately 0.14- and 0.5-times the human dose of 50 mg/m 2 based on BSA) resulted in 90% and 100% embryonic resorptions, respectively.
In mice, a single etoposide dose of 1.0 mg/kg (approximately 0.06 times the human dose of 50 mg/m 2 based on BSA) administered intraperitoneally on Days 6, 7, or 8 of gestation caused embryotoxicity, cranial abnormalities, and major skeletal malformations. An intraperitoneal dose of 1.5 mg/kg (approximately 0.10-times the human dose 50 mg/m 2 based on BSA) on Day 7 of gestation caused an increase in the incidence of intrauterine death, fetal malformations, and a significant decrease in the average fetal body weight.
Mechanism of action
12.1 Mechanism of Action Etoposide causes the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals, leading to cell cycle arrest, primarily at the G2 stage of the cell cycle, and cell death.
US FDA labelPharmacokinetics
Elimination Etoposide elimination half-life is 4 hours to 11 hours.
The mean renal clearance of etoposide is 7 mL/min/m 2 to 10 mL/min/m 2 over a dose range of 80 mg/m 2 to 600 mg/m 2 (6 times the maximum approved recommended dose).
Excretion After intravenous administration of 14 C-etoposide [100 to 124 mg/m 2 (1.2 times the maximum approved recommended dose)], mean recovery of radioactivity in the urine was 56% of the dose at 120 hours, 45% of which was excreted as etoposide; fecal recovery of radioactivity was 44% of the dose at 120 hours.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Etoposide total systemic exposure (AUC) and the maximum plasma concentration (C max) increases in dose proportional manner over dosage range of 100 to 600 mg/m 2 (6 times the maximum approved recommended dose). Etoposide does not accumulate following daily administration of 100 mg/m 2 for 4 to 5 days.
Distribution Etoposide mean volume of distribution at steady state is 7 L/m 2 to 17 L/m 2. No clinically significant amount of etoposide distributes into the CSF. Etoposide plasma protein binding is 97% in vitro (primarily albumin). Elimination Etoposide elimination half-life is 4 hours to 11 hours. Total body clearance is 16 mL/min/m 2 to 36 mL/min/m 2 over a range of 100 mg/m 2 to 600 mg/m 2 (6 times the maximum approved recommended dose).
The mean renal clearance of etoposide is 7 mL/min/m 2 to 10 mL/min/m 2 over a dose range of 80 mg/m 2 to 600 mg/m 2 (6 times the maximum approved recommended dose). Metabolism Etoposide is metabolized by opening of the lactone ring, O-demethylation and conjugation (i.e., glucuronidation and sulfation). O-demethylation occurs through CYP3A to the active catechol metabolite.
Excretion After intravenous administration of 14 C-etoposide [100 to 124 mg/m 2 (1.2 times the maximum approved recommended dose)], mean recovery of radioactivity in the urine was 56% of the dose at 120 hours, 45% of which was excreted as etoposide; fecal recovery of radioactivity was 44% of the dose at 120 hours. Specific Populations No clinically significant differences in pharmacokinetic parameters of etoposide were observed based on age and sex.
Patients with Renal Impairment Patients with impaired renal function have exhibited reduced total body clearance, increased AUC, and a lower volume of distribution at steady state. Drug Interactions In vitro studies Phenylbutazone, sodium salicylate, and aspirin displaced protein-bound etoposide in vitro.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Etoposide 20 mg/mL, 5 mL Ampule | ₱307.50–₱362.00Reference ₱307.50 | per ampule | DPRI procurement range |
| Etoposide 20 mg/mL, 5 mL Vial | ₱290.00–₱350.00Reference ₱290.00 | per vial | DPRI procurement range |
| Etoposide 100 mg Vial | ₱308.00–₱328.00Reference ₱308.00 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Etoposide |
| PNF listing | Inj.: 20 mg/mL, 5 mL ampul/vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 20 mg/mL, 10 mL vial (IV) powder 100 mg vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Avopef · AVYXA Pharma, LLC [US FDA-approved label, version 11, October 7, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acc1e443-ef7b-486f-a638-710a20e81059
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .